Home The Word Brain My Amedeo FAQ Privacy About   


Hanzi Hunter — ultra-fast Hanzi study

All 1,152 characters from the aioLingua manual

AbstractAboutThe 20 audio files

← aioLingua Chinese Online

← Chinese aioLingua PDF


  Diabetes

  Free Subscription


17.11.2025

1 Am J Ophthalmol
1 Angiology
2 Biochem Biophys Res Commun
1 BMC Ophthalmol
1 BMJ
5 Diabet Med
2 Diabetes
3 Diabetes Care
14 Diabetes Obes Metab
8 Diabetologia
2 J Am Coll Cardiol
1 J Am Soc Nephrol
1 J Biol Chem
6 J Diabetes Complications
1 J Hypertens
1 JAMA
1 Nutr Metab (Lond)
1 Ophthalmology
1 Pediatr Diabetes
7 PLoS One
1 Retina


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Ophthalmol

  1. HE L, Guo X, Yong Z, Zha Y, et al
    Choroidal-Derived Intraretinal Neovascularization Compensates for Diabetic Retinopathy Ischemia via Dual-Pathway Remodeling Post-PRP.
    Am J Ophthalmol. 2025 Nov 9:S0002-9394(25)00587.
    PubMed         Abstract available


    Angiology

  2. ENGIN M, Aydin C, Ari H
    Letter: Reperfusion of Proximal Left Circumflex Artery in Diabetic Chronic Total Occlusion Patients.
    Angiology. 2025 Nov 12:33197251395828. doi: 10.1177/00033197251395828.
    PubMed        


    Biochem Biophys Res Commun

  3. LARANJEIRA EPP, da Silva DHM, da Silva Nascimento FG, Martins AB, et al
    Canavalia brasiliensis lectin attenuates diabetes endothelial dysfunction in rats: structural basis and implication of muscarinic/insulin receptors.
    Biochem Biophys Res Commun. 2025;791:152929.
    PubMed         Abstract available

  4. HUANG C, Sun Y, Wu J, Wu D, et al
    Down-regulation of KMT2D mitigates neointimal hyperplasia following carotid artery injury in diabetic rats.
    Biochem Biophys Res Commun. 2025;791:152837.
    PubMed         Abstract available


    BMC Ophthalmol

  5. SHARMA S, Madan VV, Banerjee S
    Comparative study of corneal endothelial morphology and central corneal thickness in diabetic and non-diabetic patients at tertiary care centre.
    BMC Ophthalmol. 2025;25:640.
    PubMed         Abstract available


    BMJ

  6. LOGAN M
    Trump expands visa requirements to include diabetes and obesity.
    BMJ. 2025;391:r2400.
    PubMed        


    Diabet Med

  7. ZUO C, Chen H, Lu X, Cheng J, et al
    VEGFA-centric angiogenic genetic variants drive hypertension and dyslipidaemia susceptibility in type 2 diabetes mellitus: A multilocus synergistic cohort study.
    Diabet Med. 2025 Nov 12:e70169. doi: 10.1111/dme.70169.
    PubMed         Abstract available

  8. ERBASAN E, Aliciaslan M, Erendor F, Dandin O, et al
    Lantidra (donislecel) in type 1 diabetes: An in-depth analysis of pharmacology, clinical effectiveness, safety, and the therapeutic role of the first FDA-approved allogeneic islet cell therapy.
    Diabet Med. 2025 Nov 11:e70168. doi: 10.1111/dme.70168.
    PubMed         Abstract available

  9. WILLIS K, Shakespeare R, Chandrasekaran L, Chaudhry U, et al
    What are the perceptions and concerns of people living with diabetes and National Health Service staff around the potential implementation of AI-assisted screening for diabetic eye disease?
    Diabet Med. 2025 Nov 10:e70165. doi: 10.1111/dme.70165.
    PubMed         Abstract available

  10. JONES AD, Crossland S, Nixon JE, Siddle HJ, et al
    Comparing plantar shear strain in patients with a previous diabetes-related foot ulcer and those at low risk for ulceration using the STrain Analysis and Mapping of the Plantar Surface (STAMPS) system.
    Diabet Med. 2025 Nov 9:e70164. doi: 10.1111/dme.70164.
    PubMed         Abstract available

  11. SNG GGR, Lim GH, Tian KJY, Bee YM, et al
    Trends in admissions for hyperglycaemic emergencies and associated clinical factors in adults with type 2 diabetes in Singapore, 2013-2022.
    Diabet Med. 2025 Nov 9:e70167. doi: 10.1111/dme.70167.
    PubMed         Abstract available


    Diabetes

  12. AROSEMENA M, Chopra K, Salguero MV, Reyes D, et al
    Obstructive Sleep Apnea, Resting Heart Rate, and Glycemic Variability in Adults With Maturity-Onset Diabetes of the Young.
    Diabetes. 2025 Nov 13:db240787. doi: 10.2337/db24-0787.
    PubMed         Abstract available

  13. JING H, Shi M, Wang Y, Cao R, et al
    beta-Hydroxybutyrylation Links Ketone Metabolism to Mitochondrial Remodeling in Diabetic Cardiomyopathy.
    Diabetes. 2025 Nov 10:db250496. doi: 10.2337/db25-0496.
    PubMed         Abstract available


    Diabetes Care

  14. HALLER MJ, Kanapka L, Monzavi R, Mouse TJ, et al
    INHALE-1: A Multicenter Randomized Trial of Inhaled Technosphere Insulin in Children With Type 1 Diabetes.
    Diabetes Care. 2025 Nov 12:dc251994. doi: 10.2337/dc25-1994.
    PubMed         Abstract available

  15. WILSON CS, Falk A, Williams JM, Hilmes M, et al
    Use of Teplizumab to Modulate Stage 2 Type 1 Diabetes in Two Individuals With Autoimmune Polyendocrine Syndrome 1.
    Diabetes Care. 2025 Nov 12:dc251444. doi: 10.2337/dc25-1444.
    PubMed         Abstract available

  16. PARK CM, Thanapluetiwong S, Chen X, Oh G, et al
    Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes.
    Diabetes Care. 2025 Nov 13:dc251031. doi: 10.2337/dc25-1031.
    PubMed         Abstract available


    Diabetes Obes Metab

  17. SUN R, Wang Y, Shu H, Li L, et al
    Biweekly dosing of efsubaglutide alfa maintains glycaemic and continuous glucose monitoring control in type 2 diabetes: A randomised multicentre trial.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70262.
    PubMed         Abstract available

  18. WHARTON S, le Roux CW, Bozkurt B, Platz E, et al
    Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
    Diabetes Obes Metab. 2025 Nov 11. doi: 10.1111/dom.70263.
    PubMed         Abstract available

  19. BOYE KS, Neff LM, Perez-Nieves M, Lage MJ, et al
    Medical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study.
    Diabetes Obes Metab. 2025 Nov 11. doi: 10.1111/dom.70226.
    PubMed         Abstract available

  20. LIU S, Liu B, Zhang Y, Qiu X, et al
    Longitudinal trajectories of fasting plasma glucose predicting cardiovascular disease risk in Chinese patients with type 2 diabetes under health management.
    Diabetes Obes Metab. 2025 Nov 12. doi: 10.1111/dom.70277.
    PubMed        

  21. HARLEY M, Rentsch CT, Williamson E, Shah ASV, et al
    Ethnic differences in the comparative effectiveness of second-line type 2 diabetes medications in preventing cardiovascular disease.
    Diabetes Obes Metab. 2025 Nov 12. doi: 10.1111/dom.70273.
    PubMed         Abstract available

  22. COLEMAN RL, Adler AI, Clarke PM, McGuire DK, et al
    Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.
    Diabetes Obes Metab. 2025 Nov 12. doi: 10.1111/dom.70280.
    PubMed         Abstract available

  23. ANAGNOSTOPOULOU L, Liarakos AL, Ntanasis-Stathopoulos I, Briasoulis A, et al
    Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70288.
    PubMed         Abstract available

  24. YU W, Chen Y, Yuan M, Liang A, et al
    The global burden of early-onset type 2 diabetes (1990-2050): An age-period-cohort analysis of incidence, disparities, and projections.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70287.
    PubMed         Abstract available

  25. BOSE R, Gupta R
    Letter to the Editor in response to "Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective".
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70284.
    PubMed        

  26. ANDERSEN ES, Foghsgaard S, Vedtofte L, Pedersen MH, et al
    Five years liraglutide treatment improves glucose tolerance in women with previous gestational diabetes mellitus-Results from a randomised controlled trial.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70286.
    PubMed        

  27. THAMMAKOSOL K, Vongtangton P, Numthavaj P, Auttara-Atthakorn A, et al
    Early subcutaneous basal insulin with intravenous insulin infusion for diabetic ketoacidosis management: A systematic review and meta-analysis of randomised controlled trials.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70276.
    PubMed         Abstract available

  28. TANG WC, Reynier P, Douros A, Yu OHY, et al
    Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70264.
    PubMed         Abstract available

  29. SUN F, Zhang M, Pan Q, Shen P, et al
    The association between glycaemic control, normal weight and long-term macrovascular outcomes in people with type 2 diabetes in China: A retrospective study.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70237.
    PubMed         Abstract available

  30. ESMANN FVL, Heerfordt IM, Windfeld-Mathiasen J, Horwitz A, et al
    Anabolic androgenic steroid use and risk of diabetes mellitus in males.
    Diabetes Obes Metab. 2025 Nov 10. doi: 10.1111/dom.70283.
    PubMed         Abstract available


    Diabetologia

  31. KUUSELA S, Koskenniemi JJ, Valtanen T, Pokka T, et al
    Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative.
    Diabetologia. 2025 Nov 8. doi: 10.1007/s00125-025-06573.
    PubMed         Abstract available

  32. WU CY, Sharma A, Edwards JD, Liu PP, et al
    Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes.
    Diabetologia. 2025 Nov 8. doi: 10.1007/s00125-025-06595.
    PubMed         Abstract available

  33. WONG FS, Pearson JA, Wen L
    Is the NOD mouse a good model for type 1 diabetes?
    Diabetologia. 2025 Nov 8. doi: 10.1007/s00125-025-06579.
    PubMed         Abstract available

  34. JANSZ TT, Young KG, Hopkins R, McGovern AP, et al
    Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection.
    Diabetologia. 2025 Nov 9. doi: 10.1007/s00125-025-06577.
    PubMed         Abstract available

  35. FORTEATH C, Merchant HJ, Kocherry C, Murdoch CE, et al
    Recurrent hypoglycaemia promotes cardiomyopathy and cardiac vulnerability in a rodent model of type 1 diabetes.
    Diabetologia. 2025 Nov 10. doi: 10.1007/s00125-025-06574.
    PubMed         Abstract available

  36. PATEL SK, Ma CS, Fourlanos S, Greenfield JR, et al
    Clinical, immunogenetic and metabolic characteristics of autoantibody-negative and autoantibody-positive type 1 diabetes.
    Diabetologia. 2025 Nov 11. doi: 10.1007/s00125-025-06580.
    PubMed         Abstract available

  37. SHAH VN, Xu Y, Dabiri Y, Mohanadas HP, et al
    Association of HbA(1c) and an updated glucose management indicator (uGMI) with incident diabetic retinopathy in adults with type 1 diabetes: a longitudinal study.
    Diabetologia. 2025 Nov 11. doi: 10.1007/s00125-025-06599.
    PubMed         Abstract available

  38. BERGDAHL E, Forsander G, Milkovic L, Sundberg F, et al
    Influence of glycaemic management and BMI on cardiac autonomic markers in children with type 1 diabetes: a prospective cohort study.
    Diabetologia. 2025 Nov 11. doi: 10.1007/s00125-025-06592.
    PubMed         Abstract available


    J Am Coll Cardiol

  39. GALLI M, Benenati S, Laudani C, Simeone B, et al
    Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,592 patients.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07492.
    PubMed         Abstract available

  40. VERMA S, Catarig AM, Houlind K, Ludvik B, et al
    Sex Differences in Effectiveness of Semaglutide in Patients With Peripheral Artery Disease: The STRIDE Trial.
    J Am Coll Cardiol. 2025;86:1843-1857.
    PubMed         Abstract available


    J Am Soc Nephrol

  41. MATSOUKAS C, Tomic TT, Tonelius P, Nunez-Duran E, et al
    Streamlining the Histopathological Workflow in Diabetic Kidney Disease with Artificial Intelligence.
    J Am Soc Nephrol. 2025 Nov 12. doi: 10.1681/ASN.0000000923.
    PubMed         Abstract available


    J Biol Chem

  42. QI B, Chen Y, Lan Y, Lou Y, et al
    Metformin attenuates O-GlcNAc modification to improve renal function via AMPK/mTOR signaling in diabetic nephropathy.
    J Biol Chem. 2025 Nov 5:110909. doi: 10.1016/j.jbc.2025.110909.
    PubMed         Abstract available


    J Diabetes Complications

  43. ZHAO C, Lu X, Deng X, Xia W, et al
    The effects of Bifidobacterium animalis subsp. lactis BLa80 on glycemic control and gut microbiota in patients with T2DM: a randomized, double-blind, placebo-controlled trial.
    J Diabetes Complications. 2025;39:109195.
    PubMed         Abstract available

  44. AL-MHANNA SB, Franklin BA, Jakicic JM, Stamatakis E, et al
    Impact of aerobic exercise on cardiometabolic health in patients with diabesity: A systematic review and meta-analysis of randomized controlled trials.
    J Diabetes Complications. 2025;39:109203.
    PubMed         Abstract available

  45. LIM S, Park CY, Jeong IK, Yoon JS, et al
    Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naive type 2 diabetes: The EMPA-FIT study.
    J Diabetes Complications. 2025;40:109214.
    PubMed         Abstract available

  46. AJONIJEBU TE, Mazibuko-Mbeje SE
    The miR-200 family in type 2 diabetes: therapeutic and biomarker perspectives.
    J Diabetes Complications. 2025;40:109211.
    PubMed         Abstract available

  47. QIN R, Jiang C, Zhang M, Hou X, et al
    Prognostic value of non-alcoholic fatty liver disease, pericoronary fat attenuation index and computed tomography-derived fractional flow reserve in diabetic patients with suspected coronary artery disease.
    J Diabetes Complications. 2025;40:109216.
    PubMed         Abstract available

  48. SLATER T, Hernandez Ibarburu G, Drebert Z, Henson J, et al
    Age at type 2 diabetes diagnosis and risk of cancer: Cohort study in over 1 million individuals from the TriNetX US Collaborative Network.
    J Diabetes Complications. 2025;40:109210.
    PubMed         Abstract available


    J Hypertens

  49. LI X, Yang A, Liu X, Xu S, et al
    Screening of the key single nucleotide polymorphisms in type 2 diabetes mellitus complicated with lower extremity arterial disease by machine learning.
    J Hypertens. 2025 Nov 7. doi: 10.1097/HJH.0000000000004164.
    PubMed         Abstract available


    JAMA

  50. STAPLIN N, Roddick AJ, Neuen BL, Anker SD, et al
    Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis.
    JAMA. 2025 Nov 7:e2520835. doi: 10.1001/jama.2025.20835.
    PubMed         Abstract available


    Nutr Metab (Lond)

  51. FU Z, Chen Z, Bian S, Li L, et al
    Association of fructose-1,6-diphosphatase 1 with the progression of diabetic kidney disease.
    Nutr Metab (Lond). 2025;22:139.
    PubMed         Abstract available


    Ophthalmology

  52. DO DV, Wykoff CC, Sivaprasad S, Brown DM, et al
    Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial.
    Ophthalmology. 2025 Nov 10:S0161-6420(25)00707.
    PubMed         Abstract available


    Pediatr Diabetes

  53. NAZZAL B, Harazni L, Aqtam I, Anabtawi R, et al
    Lived Experiences of Coping With Type 1 Diabetes Among Palestinian Youth: A Qualitative Study.
    Pediatr Diabetes. 2025;2025:9014326.
    PubMed         Abstract available


    PLoS One

  54. SUGIURA-ROTH Y, Himeno T, Asano-Hayami E, Asada-Yamada Y, et al
    The DR score in RETeval electroretinogram system facilitates expeditious and uncomplicated early detection and assessment of diabetic polyneuropathy in clinical practice.
    PLoS One. 2025;20:e0336117.
    PubMed         Abstract available

  55. ANDARGE BD, Hayelom DH, Degualem SM, Bezie HE, et al
    Chronic complications among patients with type 2 diabetes in Southern Ethiopia.
    PLoS One. 2025;20:e0336666.
    PubMed         Abstract available

  56. MARTINIAKOVA M, Soltesova Prnova M, Kovacova V, Mondockova V, et al
    Insufficient impact of the aldose reductase inhibitor cemtirestat on the skeletal system in type 2 diabetic rat model.
    PLoS One. 2025;20:e0336508.
    PubMed         Abstract available

  57. LIM S, Kim JH, Hong SJ, Cha JJ, et al
    Efficacy and safety of polymer-free amphilimus-eluting stent in patients with and without diabetes mellitus: A prospective, multicenter observational study.
    PLoS One. 2025;20:e0336017.
    PubMed         Abstract available

  58. HUNDAHL A, Jespersen LN, Sildorf SM, Lindkvist EB, et al
    Fear of hypoglycemia and its association with well-being, metabolic outcomes, and psychological health: A cross-sectional study in Danish adolescents with type 1 diabetes.
    PLoS One. 2025;20:e0334243.
    PubMed         Abstract available

  59. NEUPERDT L, Du Y, Nubel J, Hapke U, et al
    Higher predicted type 2 diabetes risk is associated with worse mental health and self-rated general health among adults without known diabetes in Germany - Results of the nationwide population-based study GEDA 2022.
    PLoS One. 2025;20:e0336019.
    PubMed         Abstract available

  60. ANDERSSON-HALL U, Nord AB, Malmodin D, Holmang A, et al
    Metabolomics and glucose tolerance in pregnancy and postpartum: The PONCH study.
    PLoS One. 2025;20:e0335708.
    PubMed         Abstract available


    Retina

  61. SAHARE H
    Diabetic retinopathy phenotypes on ultrawide field retinal imaging in an Indian population.
    Retina. 2025 Nov 3. doi: 10.1097/IAE.0000000000004720.
    PubMed        


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.